Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall

Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall

• Unexplained acute hepatitis in children may be related to COVID superantigens
• How long can the patient live after heart stent surgery?
• Keytruda: The 5-year survival rate for advanced lung cancer doubled!
• Amylyx released the latest statistical analysis of new ALS drugs after being opposed by FDA panel last month
• Celine Dion is paralyzed due to muscle cramps: What are Muscle Cramps?
• Taiwan death from COVID-19 vaccination exceeds death from COVID-19 
• The world top 5 best-selling drugs in 2020

Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall. 

Moderna hopes to launch a vaccine against Covid-19, influenza and respiratory syncytial virus (a common respiratory virus) as early as fall 2023, Chief Executive Stephane Bancel said on Monday. The three-in-one vaccine booster shot.

Moderna’s chief executive, Stéphane Bancel, said the company’s goal is to have the compound vaccine available in multiple countries in the next 18 months or so.

In addition to immunizing people against Covid-19 and the flu virus, the vaccine will target respiratory syncytial virus (RSV), a common virus that often causes cold-like symptoms.

“Our goal is to develop a booster shot with only one dose per year. If people don’t want to get 2 or 3 doses of vaccine every winter, they just want to get one dose, so there will be no compliance issues.” Bancel in the world Speaking at a virtual roundtable of the World Economic Forum.

In the best-case scenario, the compound vaccine would be available in some countries by the fall of 2023, Bancel said.

He said that the RSV project is in the third phase of trials, which is the final stage of human testing; while the influenza project is in the second phase of trials and is expected to enter the third phase of trials in the second quarter of this year.

Bancel also said that Moderna’s vaccine candidate for the mutated virus Omicron has basically been developed and is about to enter the clinical stage.

The company expects to share data with regulators around March, he added.

Like Pfizer and its partner BioNTech, Moderna has developed a Covid-19 vaccine using advanced messenger RNA (mRNA) technology that differs from traditional vaccines, and has achieved impressive results. The company and its shareholders hope to see more growth from mRNA technology in the future.

Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall

(source:internet, reference only)

Disclaimer of medicaltrend.org